Examining the Efficacy and Safety of Combined Locoregional Therapy and Immunotherapy in Treating Hepatocellular Carcinoma

被引:2
|
作者
Bajestani, Nojan [1 ]
Wu, Gavin [1 ]
Hussein, Ahmed [1 ]
Makary, Mina S. [2 ]
机构
[1] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[2] Ohio State Univ, Wexner Med Ctr, Dept Radiol, Div Vasc & Intervent Radiol, 395 W 12th Ave, Columbus, OH 43210 USA
关键词
hepatocellular carcinoma; locoregional therapy; immunotherapy; combination therapy; progression-free survival; overall survival; PERCUTANEOUS RADIOFREQUENCY ABLATION; INTERNAL RADIATION-THERAPY; RANDOMIZED CONTROLLED-TRIAL; TRANSARTERIAL CHEMOEMBOLIZATION; OPEN-LABEL; PHASE-III; SURGICAL RESECTION; MICROWAVE ABLATION; Y-90; MICROSPHERES; SYSTEMIC THERAPY;
D O I
10.3390/biomedicines12071432
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
More than 800,000 people worldwide are diagnosed with HCC (hepatocellular carcinoma) each year, with approximately 700,000 deaths alone occurring in that same year. Treatment of HCC presents complex therapeutic challenges, particularly in intermediate and advanced stages. LRTs such as transarterial chemoembolization (TACE) and ablations have been the mainstay treatment for early to intermediate-stage HCC, and systemic therapies are used to treat intermediate-late-stage HCC. However, novel literature describing combining LRT with systemic therapies has shown promising results. This review explores recent advances in both liver-directed techniques for hepatocellular carcinoma, including bland transarterial embolization, chemoembolization, radioembolization, and ablative therapies in conjunction as well as with systemic therapies, with a focus on combination therapies, patient selection, procedural technique, periprocedural management, and outcomes. Our findings suggest that LRT combined with systemic therapies is a viable strategy for improving progression-free survival and time to progression for patients with intermediate-to-late-stage HCC. However, further investigation is required to refine treatment protocols and define patient cohorts that would benefit the most.
引用
收藏
页数:30
相关论文
共 50 条
  • [31] Neoadjuvant therapy and immunotherapy strategies for hepatocellular carcinoma
    Zhang, Ting
    Zhang, Lei
    Xu, Yiyao
    Lu, Xin
    Zhao, Haitao
    Yang, Huayu
    Sang, Xinting
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (06): : 1658 - 1667
  • [32] Analysis of the safety and effectiveness of TACE combined with targeted immunotherapy in the treatment of intermediate and advanced hepatocellular carcinoma
    Liu, Wenbin
    Xie, Zhiguo
    Shen, Kefeng
    Jiang, Lizhu
    Liu, Chongyan
    Ge, Yongsheng
    Yu, Jihai
    Jia, Weidong
    Ma, Jinliang
    Chen, Hao
    MEDICAL ONCOLOGY, 2023, 40 (09)
  • [33] Evaluating treatment response following locoregional therapy for hepatocellular carcinoma: A review of the available serological and radiological tools for assessment
    Cox, Daniel R. A.
    Chung, William
    Grace, Josephine
    Wong, Darren
    Kutaiba, Numan
    Ranatunga, Dinesh
    Khor, Richard
    Perini, Marcos, V
    Fink, Michael
    Jones, Robert
    Goodwin, Mark
    Dobrovic, Alex
    Testro, Adam
    Muralidharan, Vijayaragavan
    JGH OPEN, 2023, 7 (04): : 249 - 260
  • [34] Analysis of the safety and effectiveness of TACE combined with targeted immunotherapy in the treatment of intermediate and advanced hepatocellular carcinoma
    Wenbin Liu
    Zhiguo Xie
    Kefeng Shen
    Lizhu Jiang
    Chongyan Liu
    Yongsheng Ge
    Jihai Yu
    Weidong Jia
    Jinliang Ma
    Hao Chen
    Medical Oncology, 40
  • [35] Efficacy and safety of PD-1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study
    Yao, Junlin
    Zhu, Xudong
    Wu, Zhiheng
    Wei, Qing
    Cai, Yibo
    Zheng, Yu
    Hu, Xinyu
    Hu, Hong
    Zhang, Xiangyu
    Pan, Hongming
    Zhong, Xian
    Han, Weidong
    CANCER MEDICINE, 2022, 11 (19): : 3612 - 3622
  • [36] The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study
    Yang, Zeran
    Chen, Guang
    Cui, Ye
    Xiao, Guowen
    Su, Tianhao
    Yu, Jianan
    Zhang, Zhiyuan
    Han, Yanjing
    Yang, Kailan
    Jin, Long
    CANCER BIOLOGY & THERAPY, 2019, 20 (03) : 321 - 327
  • [37] Clinical Trials of Combined Molecular Targeted Therapy and Locoregional Therapy in Hepatocellular Carcinoma: Past, Present, and Future
    Kim, Hwi Young
    Park, Joong-Won
    LIVER CANCER, 2014, 3 (01) : 9 - 17
  • [38] Transarterial Chemoembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and Efficacy
    Ni, Jia-Yan
    Sun, Hong-Liang
    Luo, Jiang-Hong
    Jiang, Xiong-Ying
    Chen, Dong
    Wang, Wei-Dong
    Chen, Yao-Ting
    Huang, Jin-Hua
    Xu, Lin-Feng
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 9939 - 9950
  • [39] Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy
    Han, Ji-Won
    Yoon, Seung-Kew
    PHARMACEUTICS, 2021, 13 (09)
  • [40] Is the CRAFITY score a superior predictor of prognosis and adverse events in hepatocellular carcinoma patients treated with locoregional-immunotherapy?
    Guan, Renguo
    Mei, Jie
    Lin, Wenping
    Deng, Min
    Li, Shaohua
    Guo, Rongping
    HEPATOLOGY INTERNATIONAL, 2023, 17 (05) : 1279 - 1288